This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Concluding Remarks

Gary D. Tollefson, M.D., Ph.D.

Published: December 1, 1997

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

In closing, I would like to review the rationale for developing new atypical agents forantipsychotic pharmacotherapy and to summarize information presented at this symposium about the innovative drug olanzapine.Numerous reviews of the literature suggest that the typical antipsychotic medications arefar from optimal in treating psychosis. For example, Goff and Shader1 reported that more thanhalf of patients receiving such a drug do not respond optimally.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: